CLOV
Clover Health Investments, Corp. /de Health Care Hospital & Medical Service Plans Russell 3000
$4.46Close
$1.70 – $5.4152-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 90 · stronger than 90% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
18%
1wk
down 3.0%
price change
1mo
up 3.5%
price change
12-month return
up 29%
market up 11% ·
its own up 12%
F-score
—
— Not assessed
Altman Z″
-12.26
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 40%
year on year
EPS growth
—
latest quarter
Sales growth
up 56%
latest quarter · -6 pts
ROE
down 26%
return on equity
Free cash margin
down 4%
-$69.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.9%
$0.22 a day · 2×ATR $4.02
RS
90 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.2×
vs 50-day average
Up/down volume
0.75
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+9% vs market2 sessions after results
Financials
- Gross
- Net -4%
- Free cash -4%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $672.9M | $1.5B | $1.1B | $1.3B | $1.4B | $1.9B |
| Gross margin | — | -5% | 6% | 20% | — | — |
| Operating income | -$92.7M | -$637.0M | -$286.7M | -$205.3M | -$45.7M | -$85.5M |
| Net income | -$136.4M | -$587.8M | -$338.8M | -$213.4M | -$43.0M | -$85.5M |
| Net margin | -20% | -40% | -31% | -17% | -3% | -4% |
| Earnings per share | -$1.54 | -$1.42 | -$0.71 | -$0.44 | -$0.09 | -$0.17 |
| Free cash flow | -$119.2M | -$283.0M | -$208.4M | -$145.2M | $33.3M | -$69.0M |
| Free cash margin | -18% | -19% | -19% | -12% | 2% | -4% |
| Cash | $92.3M | $300.0M | $103.8M | $122.9M | $194.5M | $78.3M |
| Long-term debt | $106.4M | $19.9M | $0 | — | — | — |
| Shareholders' equity | -$617.1M | $535.4M | $356.9M | $286.4M | $341.1M | $308.7M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 9, 2026 | Regulation FD ↗ |
| Sep 24, 2026 | Director or officer change ↗ |
| Aug 20, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 17, 2026 | Other events ↗ |
| Jun 18, 2026 | Other events ↗ |
| Jun 16, 2026 | Director or officer change ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 10, 2026 | Other events ↗ |
| May 18, 2026 | Regulation FD ↗ |
| May 6, 2026 | Results ↗ |
| Apr 1, 2026 | Director or officer change · Other events ↗ |